Comparation of antihypertensiva activity of fosinopril and irbesartan;Comparación de la actividad antihipertensiva de fosinopril e irbesartan

Anales de Medicina Interna

Volumn 19, Issue 11, 2002, Pages 571-575

  Angulo, E ^a   Roberto Robles, Nicolás ^a   Grois, J ^a   Barquero, A ^a   Perez Miranda M ^b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b NONE

Author keywords

Hypertension; Renin angiotensin axis; Treatment

Indexed keywords

FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; FOSINOPRIL; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME;

EID: 0036858616     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Development and design of specific inhibitors of angiotensin-converting enzyme. Am J Cardiol 1982; 40: 1390-1394.
2. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. New Engl J Med 1996; 334:1 649-1654.
3. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Davis BR, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
4. The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group, a clinical trial of an angiotensin converting enzyme inhibitor in the nephropathy of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 1456-1462.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
7. Pitt B, Segal R, Martinez FA, Meurers F G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-752.
8. Lewis E, Hunsicker LG, Clarke WR, Berl T, Pons MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
9. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. N Engl J Med 2001; 345: 870-878.
10. Juncos LI. Inhibidores de la enzima de conversion. En: Rodicio JL, Romero JC, Ruilope LM (Eds.). Madrid. Fundaci6n para el Estudio de las Enfermedades Cardiovasculares. 1993. pp. 611-628.
11. McInnes GT. Angiotensin II Antagonists. Br J Cardiol 1997; 4 (7): 273-282.
12. Smith DHG, Neutel JM, Morgestern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-240.
13. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
14. Larochelle P, Flack JM, Marbury TC, Sarely P, Krieger EM, Reeves RA. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997; 80: 1613-1615.
15. Mimram A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K,et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203-208.
16. Safar ME. Arteries in clinical hypertension. Philadelphia. Lippincot-Raven Publishers. 1996.
17. Feener EP, King GL. Vascular disfunction in diabetes mellitus. Lancet. 1997; 350 (Supl. 1): 9-13.
18. Ruff D, Gazdick LP, Berman R, Goldberg AJ, Sweet CS. Comparative effect of combination drugs therapy regimens commencing with either losartan potassium, an angiotensin 11 receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14: 263-270.
19. Holwerda NJ, Fogan R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Eficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
20. Black HR, Graff A, Shutte D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Human Hypertens 1997; 11: 483-489.
21. Bremmer AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: Long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997; 19: 1263-1285.
22. Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138: S238-S245.
23. Safar ME, Laurent S, Bouthier JD, London GM, Mimran A. Effect of converting enzyme inhibition on hypertension large arteries in humans. Am J Hypertens 1986; 8: 1257-1261.
24. Levy BI, Benessiano J, Poitevin P. Safar ME. Endothelium dependent mechanical properties of the carotid artery in WKY and SHR: Role of angiotensin converting enzyme inhibition. Circ Res 1990; 66: 321-328.
25. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors:target for drug research? J Hypertens 1994; 12 (supl 2): S1-S5.